Navigation Links
Jefferson neuroscientists show anti-inflammation molecule helps fight MS-like disease
Date:11/11/2007

(PHILADELPHIA) An immune system messenger molecule that normally helps quiet inflammation could be an effective tool against multiple sclerosis (MS). Neurology researchers led by Abdolmohamad Rostami, M.D., Ph.D., professor and chair of the Department of Neurology at Jefferson Medical College of Thomas Jefferson University and the Jefferson Hospital for Neuroscience in Philadelphia, have found that the protein interkeukin-27 (IL-27) helped block the onset or reverse symptoms in animals with an MS-like disease.

The results suggest that IL-27 may someday be part of a therapy to temper over-active immune responses, which are thought to be at the heart of MS, an autoimmune disease (in which the body attacks its own tissue) affecting the central nervous system. The Jefferson neuroscientists report their findings November 11, 2007 in the journal Nature Immunology. The paper first appears in an advance online publication.

In MS, one of the most common neurological diseases affecting young adults, the myelin coating of nerve fibers becomes inflamed and scarred. As a result, messages cannot be sent through the nervous system. Dr. Rostamis team was trying to understand the mechanisms of how immune responses damage the myelin sheath and axons in the brain.

They had previously observed that IL-27, a signaling molecule called a cytokine, could suppress IL-17, another cytokine, and inflammation. They also knew that in other MS models, mice that lacked receptors for IL-27 developed excessive inflammation.

Dr. Rostami, who is also director of the Neuroimmunology Laboratory in the Department of Neurology at Jefferson Medical College, Denise Fitzgerald, Ph.D., a postdoctoral research fellow in Dr. Rostamis laboratory, and their colleagues used an animal model of MS called experimental autoimmune encephalomyelitis (EAE) for the investigation.

When the scientists gave IL-27 to the experimental mice, it significantly suppressed active disease. They saw similar effects from IL-27 in cultured cells that were transferred into nave animals, which then produced significantly milder disease. At the same time, they also showed that IL-27 enhanced the production of IL-10, a crucial anti-inflammatory cytokine.

We previously showed that IL-27 could suppress IL-17, he notes. Here we also show that IL-27 can enhance the production of IL-10. These may both be different and complementary mechanisms by which IL-27 can suppress EAE.

The findings suggest that increasing IL-27 concentrations might raise IL-10 levels, and help quell an over-active immune response. This is the first time that we have direct evidence that by actively giving IL-27 like a drug, we can suppress EAE in mice.

Dr. Rostami explains that after an MS flare-up, patients recover from the disease, though the reasons are poorly understood. We think that one of the ways that recovery from a disease flare-up occurs is that part of the immune system is shut off, suppressing the immune response in the brain. IL-27 appears to be crucial in this process, he says.

The team would like to study MS patients blood samples to see if similar processes are at work, Dr. Rostami notes. If we get similar findings in human disease, then perhaps IL-27 could be used therapeutically as a compound to suppress inflammation in the brains of MS patients.


'/>"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
2. Jefferson immunology researchers halt lethal rabies infection in brain
3. Jefferson radiation oncologists use real-time system to plant seeds against cancer
4. Jefferson researchers find personalized interventions key to improving colon cancer screening rates
5. Jefferson researchers uncover new evidence of prolactins possible role in breast cancer
6. MicroRNAs may be key to HIVs ability to hide, evade drugs, Jefferson scientists find
7. Jefferson scientists find protein may be key in developing deadly form of pancreatic cancer
8. Jefferson oncologists show focused radiation is effective as surgery against nerve tumor
9. Jefferson researchers find stem cells in degenerating spinal discs, potential for repair
10. Jefferson researchers show chemotherapy and radiation together extend lung cancer patients lives
11. New class of RNA molecules may be important in human cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , ... February 24, 2017 , ... ... business development, education, networking and recognition opportunities as well as advocacy for the ... in Holmdel, NJ on February 23. The Council's Innovation Forecast event highlights ...
(Date:2/24/2017)... , ... February 24, 2017 , ... In the Health ... be a top priority because it’s not if you will be attacked, but when.” ... when it comes to digital health care. , Improvements in auditing and monitoring have ...
(Date:2/24/2017)... ... , ... With ProGlass Prism users now have the ability to simulate prism ... position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass position offset, anchor ... Prism users are given the tools and effects to generate a fractal prismatic ...
(Date:2/24/2017)... ... ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently announced that he ... of the Management Committee when IFN was originally formed in 2002 where he was ... development of the business plan. He became the first paid employee of IFN ...
(Date:2/24/2017)... ... 24, 2017 , ... Castle Farms, the celebrated Northern ... with the winning couple announced on Feb. 14, 2017, on Facebook. The free ... vendors: A Matter of Taste, Ryan Rousseau Enterprises, A Touch of Spring and ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... DUBLIN , Feb. 24, 2017 Research and ... Analysis & Trends - Industry Forecast to 2025" report to their ... The Global Empty ... over the next decade to reach approximately $2.9 billion by 2025. ... all the given segments on global as well as regional levels presented ...
(Date:2/24/2017)... 24, 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Dry eye Drugs Price Analysis and Strategies ... eye market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Dry eye ...
(Date:2/24/2017)... 24, 2017  In conjunction with DURECT Corporation,s (Nasdaq: ... press release, you are invited to listen to a ... internet on Tuesday, March 14, 2017 at 4:30 pm ... live audio webcast of the presentation will be available ... clicking "Investor Relations."  If you are unable to participate ...
Breaking Medicine Technology: